NCT02049294View on ClinicalTrials.gov

Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions
Steroid and/or Prednisone Dependent AsthmaEosinophilic Bronchitis
Interventions
BIOLOGICAL

Omalizumab (Xolair)

DRUG

Placebo

Trial Locations (5)

Unknown

Richard Leigh, Calgary

University of British Columbia, Vancouver

McMaster University, Hamilton

University of Laval, Laval

University of Montreal, Montreal

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

McMaster University

OTHER